CD274 and neoplasm: While high levels of PD-L1 expression [12] and tumor mutational burden [13] have become pivotal biomarkers, the varying state of T-cell immunity, which greatly differs from one patient to another, has resulted in notable disparities in the effectiveness of anti-tumor treatments.